Sofosbuvir\/velpatasvir\/voxilaprevir (trade name Vosevi) is a combination drug for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.<\/p>\n
VOSEVI is not widely marketed in India. It is usually accessed through a special import process under the Named Patient Program (NPP). For assistance and guidance, you can contact us by providing complete details. Like 1. How to get access in India. 2. Imported Medicine Pricing Estimates in India (Subject to Doctor\u2019s Prescription and Regulations) 3. Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia. 4. Ensuring 100% transparency.\u00a0<\/strong><\/p>\n Need urgent access to VOSEVI? We\u2019re here to help.<\/strong><\/p>\n Call Now | Enquire Today | WhatsApp Support Available India Pharma Network (IPN):<\/strong> Headquartered in New Delhi, with branch offices in Mumbai, Delhi, Gurugram, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedabad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tirupur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.<\/strong>\u00a0IPN facilitates access to medicines through legally compliant import pathways. Such access is arranged on a Named Patient basis and is intended strictly for personal use, in accordance with applicable regulations and subject to a valid medical prescription and necessary approvals.<\/p>\n NEWS \/ UPDATES<\/strong><\/p>\n <\/p>\n India Pharma Network acts solely as a facilitator for FETROJA (cefiderocol) access. IPN does not manufacture, sell, or promote medicines and does not provide medical advice. All imports are:<\/p>\n The prescribing physician remains solely responsible for dosage, therapy, and clinical decisions.<\/p>\n","protected":false},"excerpt":{"rendered":" VOSEVI is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, velpatasvir, an HCV NS5A inhibitor, and voxilaprevir, an HCV NS3\/4A protease inhibitor, and is indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have (1, 2.2, 14): \u2022 genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. \u2022 genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. o Additional benefit of VOSEVI over sofosbuvir\/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.<\/p>\nGet Help for VOSEVI Import<\/h4>\n
\n
\n<\/strong>Mobile\/WhatsApp:\u00a0Mr. Tarun: +91 9891 296 838 | \u00a0Mr. Neeraj: +91 9811 747 774.\u00a0<\/strong>
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/p>\n\n
Compliance & Disclaimer<\/h4>\n
\n
VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n VOSEVI<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n sofosbuvir, velpatasvir, and voxilaprevir<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n \u2022 Tablets: 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n Gilead Sciences, Inc.<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n